244 related articles for article (PubMed ID: 8215474)
21. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
[TBL] [Abstract][Full Text] [Related]
22. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
[No Abstract] [Full Text] [Related]
23. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Vogler WR; Velez-Garcia E; Omura G; Raney M
Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
[No Abstract] [Full Text] [Related]
24. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
Gan To Kagaku Ryoho; 1989 May; 16(5):2019-23. PubMed ID: 2730091
[TBL] [Abstract][Full Text] [Related]
25. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
[TBL] [Abstract][Full Text] [Related]
26. [Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
Helg C; Chapuis B; Grob JP; Pugin P
Schweiz Med Wochenschr; 1990 Apr; 120(15):548-52. PubMed ID: 2336558
[TBL] [Abstract][Full Text] [Related]
27. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
[TBL] [Abstract][Full Text] [Related]
28. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
Gustavsson A; Olofsson T
Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
[TBL] [Abstract][Full Text] [Related]
29. Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
Resegotti L
Leukemia; 1992; 6 Suppl 2():72-5. PubMed ID: 1578948
[TBL] [Abstract][Full Text] [Related]
30. Intensification in post-remission treatment of adult acute non lymphocytic leukemia.
Petti MC; Aloe Spiriti MA; Carella AM; Fioritoni G; Resegotti L; Rizzoli V; Tabilio A; Visani G; Vegna ML; Mandelli F
Haematologica; 1989; 74(3):267-71. PubMed ID: 2511095
[TBL] [Abstract][Full Text] [Related]
31. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
Sampi K; Honda T; Hayashi Y; Hattori M
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
[TBL] [Abstract][Full Text] [Related]
32. Idarubicin in combination with etoposide and cytarabine in adult acute non-lymphoblastic leukaemia (ANLL).
Carella AM; Pungolino E; Piatti G; Giordano D; Cerri R; Risso M; Nati S
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():50-1. PubMed ID: 2713562
[No Abstract] [Full Text] [Related]
33. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Beksaç M; Arslan O; Koç H; Akan H; Ilhan O; Arat M; Ozcan M; Gürman G; Konuk N; Uysal A
Med Oncol; 1998 Sep; 15(3):183-90. PubMed ID: 9819795
[TBL] [Abstract][Full Text] [Related]
34. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
Petti MC; Mandelli F
Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
[No Abstract] [Full Text] [Related]
35. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
[No Abstract] [Full Text] [Related]
36. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
Patterson D; Kravtsova VM; Petrova EM; Zabelina TS; Balaian LN
Ter Arkh; 1987; 59(12):81-6. PubMed ID: 3482131
[TBL] [Abstract][Full Text] [Related]
37. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
[TBL] [Abstract][Full Text] [Related]
38. Selective use of daunorubicin for remission-induction chemotherapy in acute non-lymphoblastic leukemia.
Shaikh BS; Dougherty JB; Hamilton RW; Ballard JO; Patel SB; Gevirtz NR; Eyster ME
Cancer; 1980 Oct; 46(8):1731-4. PubMed ID: 6932996
[TBL] [Abstract][Full Text] [Related]
39. [A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
Lou FD; Zhou Q; Meng FY
Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):146-8, 187. PubMed ID: 1395925
[TBL] [Abstract][Full Text] [Related]
40. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]